SCHEMBL7238359

SCHEMBL7238359

N#Cc1cnc(Nc2cc(CN3CCC(O)CC3)ccn2)s1

nearest known ligand 0.75

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234522 0.88 KDR (0.73) KDR
SCHEMBL7227257 0.88 KDR (0.77) KDR
SCHEMBL5742138 0.85 KDR (1.00) KDR
SCHEMBL6179139 0.85 KDR (1.00) KDR
SCHEMBL6179438 0.85 KDR (1.00) KDR
SCHEMBL7230112 0.84 KDR (0.69) KDR
SCHEMBL6178356 0.84 KDR (0.74) KDR
SCHEMBL5742011 0.84 KDR (1.00) KDR
SCHEMBL6177027 0.83 KDR (1.00) KDR
SCHEMBL6178074 0.83 KDR (1.00) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586424-B2 Anticancer agents; anticholesterol agents MERCK & CO., INC. 2003-07-01 US disclosed
US-6586423-B2 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy MERCK & CO., INC. 2003-07-01 US disclosed